Reviewed by Gabriel Brocklesby · Last updated
Both topics are often associated with recovery-focused clinic listings. Compare provider transparency, consultation model, and follow-up structure.
BPC-157 and TB-500 are frequently referenced in recovery, rehabilitation, and sports performance clinic contexts. Both appear in listings as part of broader protocols rather than standalone services, so the quality of clinical oversight matters more than the name itself. Use this comparison to frame questions for clinics about evidence, monitoring, and suitability.
A synthetic peptide derived from a gastric protein fragment. Often cited in recovery and regenerative medicine listings with limited human evidence.
A synthetic peptide referenced in recovery and performance listings, typically alongside other regenerative or rehabilitation services.
| Category | BPC-157 | TB-500 |
|---|---|---|
| Directory context | Recovery-focused, rehabilitation, and regenerative medicine clinic discussions. | Recovery and performance-oriented listings, often linked to soft-tissue or rehabilitation framing. |
| Common goals | Recovery support, tissue-repair discussions, and broader rehabilitation conversations. | Soft-tissue recovery, performance support, and broader rehabilitation conversations. |
| Guidance note | Informational directory topic only; clinics should explain evidence limits, sourcing, and monitoring clearly. | Informational directory topic only; clinics should explain evidence limits, sourcing, and monitoring clearly. |
Next step
Use city pages and peptide-specific pages to move from general research into actual provider shortlists. That usually gives a better buying picture than comparing drug names alone.
London, United Kingdom
Doctor-led peptide advisory consultations in central London. Every protocol is built around comprehensive bloodwork and personally led by Dr Ethan Hausman-Marquis (PhD, Karolinska Institute), with compounds sourced from GMP-certified, EMA-regulated pharmacies.
London, United Kingdom
Menon Health is a Mayfair-based peptide therapy clinic founded by Dr Mukil Menon, a GMC-registered physician and one of the first doctors to prescribe medical peptide therapy in the UK. Before establishing Menon Health, Dr Menon served as UK medical director at Koniver Wellness, launching the clinic at Soho House London. He continues to practise within the NHS alongside his private consultations, ensuring his protocols stay grounded in current medical standards. The clinic offers doctor-led, prescription-based peptide therapy alongside regenerative cell complex treatments, bloods and diagnostics, and IV therapy. All formulations are sourced from GMP-certified, EMA-regulated pharmacies and dispensed as pre-filled pens, vials, or multi-peptide syringes — Menon Health's approach to combining multiple peptides in a single dose is designed to improve precision and patient adherence. Based at 64 North Row in Mayfair, London, Menon Health serves patients across the UK, Europe, Canada, and the United States, with consultations available in person or remotely.
Los Angeles, CA, USA
Iv Glow Bar is an approved peptide clinic listing in Los Angeles. Services reference semaglutide, tirzepatide, bpc-157, cjc-1295, ipamorelin.
Glendale, CA, USA
Wellness Club 365 is an approved peptide clinic listing in USA. Services reference semaglutide, tirzepatide, bpc-157, cjc-1295, ipamorelin, testosterone-therapy.
BPC-157 is a synthetic peptide commonly referenced in recovery, regenerative medicine, and rehabilitation clinic contexts. It is often discussed in relation to tissue repair, gut support, and post-injury recovery pathways, though human evidence remains limited and clinics should explain that context clearly.
Clinics that mention BPC-157 usually position it within recovery, injury support, or broader performance optimisation discussions rather than as an isolated service line.
UK availability is more limited than many US search results suggest, so UK readers should also review the BPC-157 UK clinic context before comparing providers.
TB-500 is another recovery-oriented peptide topic that appears in clinic listings linked to soft-tissue recovery, rehabilitation, and performance support. It is often referenced alongside BPC-157, but clinics vary widely in how they explain evidence, legal context, and supervision.
Clinics generally reference TB-500 in broader recovery and rehabilitation pathways, especially when they market toward performance, injury support, or regenerative medicine audiences.
In directory terms, BPC-157 is often associated with gut and recovery discussions, while TB-500 appears more often in performance and soft-tissue recovery conversations. Both should be treated as informational peptide topics rather than guaranteed outcomes, and both require clinics to explain supervision, rationale, and monitoring.
Neither is automatically better. The stronger signal is whether a clinic can explain why a protocol is being considered, what evidence supports it, how risks are managed, and what follow-up is included.
Do clinics often mention BPC-157 and TB-500 together?
Yes. Many recovery-oriented clinics reference them together within broader rehabilitation or performance discussions.
Are these pages treatment recommendations?
No. They are informational comparison pages designed to help users research how clinics frame these peptide topics.
Where should I compare clinics that reference these peptides?
Start with Miami, Los Angeles, or New York.
Neither is inherently better without clinical context. Prioritise clinics that can explain why a peptide is included, how it is monitored, and what outcomes they track. The provider’s governance model should drive your decision more than the peptide name.
For clinics
Get featured on this page and reach patients actively looking for peptide therapy, GLP-1 treatments, recovery support, and longevity care.